Assessment and comparison of viability assays for cellular products-Reference-Cited by-同舟云学术

Assessment and comparison of viability assays for cellular products

Published:2024-02 Issue:2 Volume:26 Page:201-209
ISSN:1465-3249
Container-title:Cytotherapy
language:en
Short-container-title:Cytotherapy

Author:

Cai Yihua^ORCID,Prochazkova Michaela,Kim Yong-Soo,Jiang Chunjie,Ma Jinxia,Moses Larry,Martin Kathryn,Pham Victoria,Zhang Nan^ORCID,Highfill Steven L.^ORCID,Somerville Robert P.,Stroncek David F.^ORCID,Jin Ping

Funder

Clinical Center

NIH

Publisher

Elsevier BV

Subject

Cancer Research,Transplantation,Cell Biology,Genetics (clinical),Oncology,Immunology,Immunology and Allergy

Reference32 articles.

1. Outcomes from a cell viability workshop: fit-for-purpose considerations for cell viability measurements for cellular therapeutic products;Pierce;Cell & Gene Therapy Insights,2021

2. ISO 20391–1:2018 Biotechnology—Cell counting—Part 1: General guidance on cell counting methods. International Organization for Standardization. ISO/TC 276 Biotechnology, 2018.

3. Improving CAR T cell therapy by optimizing critical quality attributes;Reddy;Semin Hematol,2020

4. Post-thaw viability of cryopreserved peripheral blood stem cells (PBSC) does not guarantee functional activity: important implications for quality assurance of stem cell transplant programmes;Morgenstern;Br J Haematol,2016

5. Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics;Panch;Mol Ther,2019

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emergent emm4 group A Streptococcus evidences a survival strategy during interaction with immune effector cells;Infection and Immunity;2024-07-11

2. Emergentemm4group AStreptococcusevidences a survival strategy during interaction with immune effector cells;2024-04-10